Curanex Pharmaceuticals Inc
CURX
$0.60
-$0.01-1.78%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 163.27% | 261.06% | 1,396.91% | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 163.27% | 261.06% | 1,396.91% | -- | -- |
| Operating Income | -163.27% | -261.06% | -1,396.91% | -- | -- |
| Income Before Tax | -217.29% | -335.45% | -1,773.06% | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -217.29% | -335.45% | -1,773.06% | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -217.29% | -335.45% | -1,773.06% | -- | -- |
| EBIT | -163.27% | -261.06% | -1,396.91% | -- | -- |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 89.61% | 78.85% | -404.36% | -- | -- |
| Normalized Basic EPS | 91.31% | 80.72% | -396.00% | -- | -- |
| EPS Diluted | 89.61% | 78.85% | -404.36% | -- | -- |
| Normalized Diluted EPS | 91.31% | 80.72% | -396.00% | -- | -- |
| Average Basic Shares Outstanding | 2,191.34% | 3,009.84% | 2,034.84% | -- | -- |
| Average Diluted Shares Outstanding | 2,191.34% | 3,009.84% | 2,034.84% | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |